{"id":69858,"date":"2026-07-13T16:26:43","date_gmt":"2026-07-13T08:26:43","guid":{"rendered":"https:\/\/flcube.com\/?p=69858"},"modified":"2026-07-13T16:26:43","modified_gmt":"2026-07-13T08:26:43","slug":"shionogi-nagasaki-university-and-mmv-secure-jpy-910-million-ghit-fund-support-for-novel-malaria-prevention-drug-development","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69858","title":{"rendered":"Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Shionogi &amp; Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/4507:TYO\">TYO: 4507<\/a>) announced that it has entered into a <strong>joint research agreement<\/strong> with <strong>Nagasaki University<\/strong> and the not-for-profit research and development organization, <strong>Medicines for Malaria Venture (MMV)<\/strong>, for the discovery of a <strong>novel malaria prevention drug<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-partnership-framework-amp-funding\" class=\"wp-block-heading\">Partnership Framework &amp; Funding<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Shionogi &amp; Co., Ltd.; Nagasaki University; Medicines for Malaria Venture (MMV)<\/td><\/tr><tr><td><strong>Funding Source<\/strong><\/td><td>Global Health Innovative Technology Fund (GHIT Fund)<\/td><\/tr><tr><td><strong>Funding Amount<\/strong><\/td><td>Approximately JPY 910 million (~USD 6.2 million)<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>13 Jul 2026<\/td><\/tr><tr><td><strong>Development Candidate<\/strong><\/td><td>S-048133 (identified from ongoing collaboration)<\/td><\/tr><tr><td><strong>Research Phase<\/strong><\/td><td>Preclinical development<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">This expanded collaboration builds upon a successful partnership initiated in March 2023, which has now yielded a promising development candidate for malaria prevention.<\/p>\n\n\n\n<h2 id=\"h-research-background-amp-progress\" class=\"wp-block-heading\">Research Background &amp; Progress<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Initial Collaboration Start:<\/strong> March 2023<\/li>\n\n\n\n<li><strong>Original Objective:<\/strong> Discovery of new antimalarial treatments and preventive drugs<\/li>\n\n\n\n<li><strong>Current Milestone:<\/strong> Identification of development candidate S-048133<\/li>\n\n\n\n<li><strong>Next Phase:<\/strong> Joint preclinical development under expanded agreement<\/li>\n\n\n\n<li><strong>Funding Recognition:<\/strong> Selected for GHIT Fund support based on scientific merit and global health impact potential<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">Malaria remains one of the world&#8217;s most significant infectious disease challenges, with an estimated 249 million cases and 608,000 deaths globally in 2022, primarily affecting children under five in sub-Saharan Africa.<\/p>\n\n\n\n<h2 id=\"h-strategic-partnership-dynamics\" class=\"wp-block-heading\">Strategic Partnership Dynamics<\/h2>\n\n\n\n<h3 id=\"h-shionogi-amp-co-ltd-tyo-4507\" class=\"wp-block-heading\">Shionogi &amp; Co., Ltd. (TYO: 4507)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Role:<\/strong> Pharmaceutical development expertise and compound optimization<\/li>\n\n\n\n<li><strong>Core Competency:<\/strong> Anti-infective drug discovery and development<\/li>\n\n\n\n<li><strong>Global Health Commitment:<\/strong> Long-standing involvement in infectious disease therapeutics<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-nagasaki-university\" class=\"wp-block-heading\">Nagasaki University<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Role:<\/strong> Academic research leadership and malaria expertise<\/li>\n\n\n\n<li><strong>Core Competency:<\/strong> Tropical medicine and parasitology research<\/li>\n\n\n\n<li><strong>Geographic Advantage:<\/strong> Historical focus on infectious diseases in Asia-Pacific region<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-medicines-for-malaria-venture-mmv\" class=\"wp-block-heading\">Medicines for Malaria Venture (MMV)<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Role:<\/strong> Product development partnership coordination and global access strategy<\/li>\n\n\n\n<li><strong>Core Competency:<\/strong> Antimalarial drug development and deployment<\/li>\n\n\n\n<li><strong>Mission Alignment:<\/strong> Dedicated to reducing malaria burden in endemic countries<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The tripartite collaboration leverages complementary strengths across industry, academia, and global health non-profit sectors.<\/p>\n\n\n\n<h2 id=\"h-global-health-context-amp-market-need\" class=\"wp-block-heading\">Global Health Context &amp; Market Need<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Current Status<\/th><th>Impact of S-048133<\/th><\/tr><\/thead><tbody><tr><td><strong>Global Malaria Burden<\/strong><\/td><td>249 million cases annually<\/td><td>Potential prevention tool<\/td><\/tr><tr><td><strong>At-Risk Population<\/strong><\/td><td>3.7 billion people globally<\/td><td>Expanded protection coverage<\/td><\/tr><tr><td><strong>Current Prevention Options<\/strong><\/td><td>Limited chemoprevention agents<\/td><td>Novel mechanism of action<\/td><\/tr><tr><td><strong>Drug Resistance Concerns<\/strong><\/td><td>Growing resistance to existing agents<\/td><td>New chemical class potential<\/td><\/tr><tr><td><strong>Vulnerable Populations<\/strong><\/td><td>Children, pregnant women, travelers<\/td><td>Targeted prevention strategies<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The development of new malaria prevention drugs is critical given increasing resistance to current antimalarial agents and the need for diverse intervention tools to support elimination efforts.<\/p>\n\n\n\n<h2 id=\"h-ghit-fund-support-significance\" class=\"wp-block-heading\">GHIT Fund Support Significance<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Funding Amount:<\/strong> JPY 910 million represents substantial non-dilutive funding<\/li>\n\n\n\n<li><strong>Selection Criteria:<\/strong> Based on scientific innovation, feasibility, and global health impact<\/li>\n\n\n\n<li><strong>Strategic Validation:<\/strong> GHIT Fund&#8217;s backing validates the project&#8217;s potential significance<\/li>\n\n\n\n<li><strong>Implementation Timeline:<\/strong> Accelerated preclinical development enabled by dedicated funding<\/li>\n\n\n\n<li><strong>Global Access Commitment:<\/strong> Aligns with GHIT Fund&#8217;s mission of equitable access to innovations<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The GHIT Fund is a Japanese public-private partnership that supports R&amp;D for neglected diseases affecting low- and middle-income countries.<\/p>\n\n\n\n<h2 id=\"h-development-pipeline-amp-next-steps\" class=\"wp-block-heading\">Development Pipeline &amp; Next Steps<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Current Stage:<\/strong> Preclinical development of S-048133<\/li>\n\n\n\n<li><strong>Development Pathway:<\/strong> IND-enabling studies leading to clinical trials<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Coordination with international regulatory authorities<\/li>\n\n\n\n<li><strong>Manufacturing Planning:<\/strong> Scalable production process development<\/li>\n\n\n\n<li><strong>Access Planning:<\/strong> Early engagement with malaria-endemic country stakeholders<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The timeline for clinical development will depend on successful completion of preclinical studies, with Phase I trials potentially commencing within 18-24 months.<\/p>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Global Health Leadership:<\/strong> Positions Shionogi as contributor to major infectious disease challenge<\/li>\n\n\n\n<li><strong>Scientific Innovation:<\/strong> Advances novel chemical approaches to malaria prevention<\/li>\n\n\n\n<li><strong>Partnership Model:<\/strong> Demonstrates effective industry-academia-nonprofit collaboration<\/li>\n\n\n\n<li><strong>Sustainable Development Goals:<\/strong> Contributes to SDG 3 (Good Health and Well-being)<\/li>\n\n\n\n<li><strong>Commercial-Social Balance:<\/strong> Addresses unmet medical need while building scientific reputation<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding research progress, development timelines, and funding utilization. Actual results may differ due to risks including research outcomes, regulatory requirements, and global health policy changes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shionogi &amp; Co., Ltd. (TYO: 4507) announced that it has entered into a joint research&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[423,2673],"class_list":["post-69858","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-shionogi","tag-tyo-4507"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shionogi &amp; Co., Ltd. (TYO: 4507) announced that it has entered into a joint research agreement with Nagasaki University and the not-for-profit research and development organization, Medicines for Malaria Venture (MMV), for the discovery of a novel malaria prevention drug.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69858\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development\" \/>\n<meta property=\"og:description\" content=\"Shionogi &amp; Co., Ltd. (TYO: 4507) announced that it has entered into a joint research agreement with Nagasaki University and the not-for-profit research and development organization, Medicines for Malaria Venture (MMV), for the discovery of a novel malaria prevention drug.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69858\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-13T08:26:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69858#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69858\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development\",\"datePublished\":\"2026-07-13T08:26:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69858\"},\"wordCount\":620,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Shionogi\",\"TYO: 4507\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69858#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69858\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69858\",\"name\":\"Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-13T08:26:43+00:00\",\"description\":\"Shionogi & Co., Ltd. (TYO: 4507) announced that it has entered into a joint research agreement with Nagasaki University and the not-for-profit research and development organization, Medicines for Malaria Venture (MMV), for the discovery of a novel malaria prevention drug.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69858#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69858\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69858#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development - Insight, China&#039;s Pharmaceutical Industry","description":"Shionogi & Co., Ltd. (TYO: 4507) announced that it has entered into a joint research agreement with Nagasaki University and the not-for-profit research and development organization, Medicines for Malaria Venture (MMV), for the discovery of a novel malaria prevention drug.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69858","og_locale":"en_US","og_type":"article","og_title":"Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development","og_description":"Shionogi & Co., Ltd. (TYO: 4507) announced that it has entered into a joint research agreement with Nagasaki University and the not-for-profit research and development organization, Medicines for Malaria Venture (MMV), for the discovery of a novel malaria prevention drug.","og_url":"https:\/\/flcube.com\/?p=69858","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-13T08:26:43+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69858#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69858"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development","datePublished":"2026-07-13T08:26:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69858"},"wordCount":620,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Shionogi","TYO: 4507"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69858#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69858","url":"https:\/\/flcube.com\/?p=69858","name":"Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-13T08:26:43+00:00","description":"Shionogi & Co., Ltd. (TYO: 4507) announced that it has entered into a joint research agreement with Nagasaki University and the not-for-profit research and development organization, Medicines for Malaria Venture (MMV), for the discovery of a novel malaria prevention drug.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69858#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69858"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69858#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shionogi, Nagasaki University and MMV Secure JPY 910 Million GHIT Fund Support for Novel Malaria Prevention Drug Development"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69858","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69858"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69858\/revisions"}],"predecessor-version":[{"id":69859,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69858\/revisions\/69859"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69858"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69858"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69858"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}